|
Variable
|
Entire cohort (n = 71)
|
Normal-Mild (n = 58)
|
Moderate-Severe (n = 13)
|
P-value
|
|---|
|
Average age
|
59.7
|
60.4
|
59.7
|
0.79
|
|
Gender
|
|
Males
|
50 (70.4 %)
|
46 (79.3 %)
|
8 (61.5 %)
|
0.65
|
|
Females
|
21 (29.6 %)
|
12 (20.7 %)
|
5 (38.5 %)
|
0.51
|
|
TNM staging
|
|
Early
|
7 (9.9 %)
|
12 (20.7 %)
|
3 (23.1 %)
|
0.35
|
|
Advanced
|
64 (90.1 %)
|
46 (79.3 %)
|
10 (76.9 %)
|
0.32
|
|
Site
|
|
Oral Cavity/Oropharynx
|
39 (54.9 %)
|
29 (50.0 %)
|
10 (76.9 %)
|
0.07
|
|
Larynx
|
9 (12.7 %)
|
9 (15.5 %)
|
0 (0.0 %)
|
0.11
|
|
Other
|
23 (32.4 %)
|
20 (34.5 %)
|
3 (23.1 %)
|
0.32
|
|
Reconstruction
|
|
Osseocutaneous FF
|
11 (15.5 %)
|
9 (15.5 %)
|
2 (15.4 %)
|
1.00
|
|
Fasciocutaneous FF
|
58 (81.7 %)
|
48 (82.8 %)
|
10 (76.9 %)
|
0.24
|
|
Pedicled/Rotational
|
2 (2.8 %)
|
1 (1.7 %)
|
1 (7.7 %)
|
0.35
|
|
Adjuvant therapy
|
|
Radiation therapy (RT)
|
57 (80.3 %)
|
46 (79.3 %)
|
11 (84.6 %)
|
0.56
|
|
Chemotherapy (C)
|
32 (45.1 %)
|
26 (44.8 %)
|
6 (46.2 %)
|
0.22
|
|
Chemoradiation Therapy (CRT)
|
32 (45.1 %)
|
26 (44.8 %)
|
6 (46.2 %)
|
0.22
|
|
Pre-treatment substance abuse
|
16 (22.5 %)
|
15 (25.9 %)
|
1 (7.7 %)
|
0.82
|
|
Supports/Caregivers available
|
61 (85.9 %)
|
48 (82.8 %)
|
11 (84.6 %)
|
0.81
|
|
Charlson comorbidity index
|
Mean 70.2 %, Median 77 %
|
Mean 70.2 %, Median 77 %
|
Mean 70.2 %, Median 90 %
|
0.65
|
-
FF free flap, RT radiation therapy, CRT chemoradiation therapy, C chemotherapy
